4JSU

Yeast 20S proteasome in complex with the dimerized linear mimetic of TMC-95A - yCP:3a

4JSU の概要

• エントリーDOI: 10.2210/pdb4jsu/pdb
• 関連するPDBエントリー: 1JD2 1RYP 4JSQ 4JT0
• 関連するBIRD辞書のPRD_ID: PRD_001044
• 分子名称: Proteasome subunit alpha type-2, Proteasome subunit beta type-4, Proteasome subunit beta type-5, ... (17 entities in total)
• 機能のキーワード: ups, proteasome, drug discovery, non-covalent reversible inhibition, bivalence, tmc-95a derivatives, ntn hydrolase, non-lysosomal protein breakdown, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Saccharomyces cerevisiae (yeast); 詳細
• 細胞内の位置: Cytoplasm: P23639 P22141 P30656 P23724 P30657 P38624 P23638 P40303 P32379 P40302 P21242 P21243 P25043 P25451
• タンパク質・核酸の鎖数: 32
• 化学式量合計: 733287.75

構造登録者

Desvergne, A.,Genin, E.,Marechal, X.,Gallastegui, N.,Dufau, L.,Richy, N.,Groll, M.,Vidal, J.,Reboud-Ravaux, M. (登録日: 2013-03-22, 公開日: 2013-05-01, 最終更新日: 2023-11-15)

主引用文献

Desvergne, A.,Genin, E.,Marechal, X.,Gallastegui, N.,Dufau, L.,Richy, N.,Groll, M.,Vidal, J.,Reboud-Ravaux, M.
Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome
J.Med.Chem., 56:3367-3378, 2013

PubMed Abstract: Noncovalent proteasome inhibitors introduce an alternative mechanism of inhibition to that of covalent inhibitors used in cancer therapy. Starting from a noncovalent linear mimic of TMC-95A, a series of dimerized inhibitors using polyaminohexanoic acid spacers has been designed and optimized to target simultaneously two of the six active sites of the eukaryotic 20S proteasome. The homodimerized compounds actively inhibited chymotrypsin-like (Ki = 6-11 nM) and trypsin-like activities, whereas postacid activity was poorly modified. The noncovalent binding mode was ascertained by X-ray crystallography of the inhibitors complexed with the yeast 20S proteasome. The inhibition of proteasomal activities in human cells was evaluated. The use of the multivalency inhibitor concept has produced highly efficient and selective noncovalent compounds (no inhibition of calpain and cathepsin) that have potential therapeutic advantages compared to covalent binders such as bortezomib and carfilzomib.

PubMed: 23540790
DOI: 10.1021/jm4002007

実験手法

X-RAY DIFFRACTION (2.9 Å)